Metrics as of 10/17/2026, 08:49 AM (Berlin time), refresh in progress.
Sionna Therapeutics Stock
Sionna Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael Cloonan
- Employees
- 59
- Market cap
- $176 M
- IPO
- 07/02/2025
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial;…
Sionna Therapeutics stock: price history
1D
-4.7%
1W
-20.6%
1M
-44.7%
6M
-91.1%
YTD
-90.5%
1Y
-88.1%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~505% stronger price swings than usual
Ask the agents about Sionna Therapeutics
Analyst assessment of Sionna Therapeutics
PRICE TARGET LOW
US$5.00
CONSENSUS
US$27.40
MEDIAN
US$7.00
PRICE TARGET HIGH
US$60.00
0
STRONG BUY
3
BUY
4
HOLD
1
SELL
0
STRONG SELL
8
TOTAL · Hold
As of: 15/09/2026
Sionna Therapeutics stock metrics
P/E
-1.78
P/B
0.66
EV/EBITDA
-1.29
RETURN ON EQUITY
-11.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
52.2%
FLOAT SHARES
23,559,458
AVG. DAILY VOLUME (30D)
1,318,164
Insider transactions (SEC)
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
Fitzpatrick Jennifer
Fitzpatrick Jennifer
McKee Charlotte
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.7%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Sionna Therapeutics stock
What does Sionna Therapeutics do?
Sionna Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael Cloonan, the company employs around 59 people.
The IPO was on 07/02/2025; the stock trades on NASDAQ under the ticker SION.
What do analysts say about Sionna Therapeutics stock?
8 analysts rate the stock, the consensus is Hold (as of 15/09/2026).
The average price target is US$27.40, ranging from US$5.00 to US$60.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does Sionna Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 505% stronger than usual.
Does Sionna Therapeutics pay a dividend?
No, Sionna Therapeutics currently does not pay a dividend.
Which stocks are comparable to Sionna Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Sionna Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Sionna Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.